SpringWorks Therapeutics, Inc. announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. Dr. Lin joins SpringWorks from Black Diamond Therapeutics, where he was Senior Vice President, Translational Science and Discovery Biology.

Prior to Black Diamond, Dr. Lin led the translational biomarker research team and Immuno-Oncology precision medicine efforts at EMD Serono. Before EMD Serono, Dr. Lin had extensive experience in leading multidisciplinary drug discovery teams and biology groups at global pharmaceutical companies including Bristol-Myers Squibb, Roche, and Janssen Pharmaceuticals. Dr. Lin earned a Ph.D. in Biochemistry from University of Missouri-Columbia and completed postdoctoral research in Molecular Biology and Pharmacology at Washington University in St.

Louis.